GuidelineJournal of general internal medicine2009
Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.
Guideline in Journal of general internal medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.JAMA network open · 2022Trial
- Trial
- Disparities in genetic services utilization in a random sample of young breast cancer survivors.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Trial
- Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.BMC health services research · 2018Trial
- A randomized, controlled trial to increase discussion of breast cancer in primary care.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Trial
- Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Trial
- Impact of Affordable Care Act Provisions on the Racial Makeup of Patients Enrolled at a Deep South, High-Risk Breast Cancer Clinic.Journal of racial and ethnic health disparities · 2025Article
- The breast cancer genetic testing experience: probing the potential utility of an online decision aid in risk perception and decision making.BMC cancer · 2025Article
- No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives inGenes · 2021Article
- Evaluation and comparison of hereditary Cancer guidelines in the population.Hereditary cancer in clinical practice · 2021Article
- Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.BMC cancer · 2021Article
- Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey.Journal of personalized medicine · 2019Article
- Painting a portrait: Analysis of national health survey data for cancer genetic counseling.Cancer medicine · 2019Article
- An Applied Framework in Support of Shared Decision Making aboutAMIA ... Annual Symposium proceedings. AMIA Symposium · 2018Article
- Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.Journal of genetic counseling · 2017Article
- Expert and Advocacy Group Consensus Findings on the Horizon of Public Health Genetic Testing.Healthcare (Basel, Switzerland) · 2016Article
- Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet.NPJ genomic medicine · 2016Article
- Public awareness of genetic nondiscrimination laws in four states and perceived importance of life insurance protections.Journal of genetic counseling · 2015Article
- Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 National Health Interview Surveys.American journal of preventive medicine · 2014Article
- Validity of self-reported genetic counseling and genetic testing use among breast cancer survivors.Journal of cancer survivorship : research and practice · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBRCA1/2 testing is one of the most well-established genetic tests to predict cancer risk. Guidelines are available to help clinicians determine who will benefit most from testing.
objectiveTo identify women at high risk of hereditary breast and ovarian cancer and estimate their awareness of and experience with genetic testing for cancer risk.
designAnalyses of the 2000 and 2005 National Health Interview Surveys.
participantsWomen with no personal history of breast or ovarian cancer (n = 35,116). MEASUREMENTS: Risk of hereditary breast or ovarian cancer based on self-reported family history of cancer and national guidelines; self-reported awareness of genetic testing for cancer risk; discussion of genetic testing for cancer risk with a health professional; having undergone genetic testing for breast/ovarian cancer risk.
resultsUsing guideline criteria, 0.96% of women were identified as being at high risk of hereditary breast and ovarian cancer. Among high-risk women, 54.04% were aware of genetic testing for cancer risk, 10.39% had discussed genetic testing with a health professional, and 1.41% had undergone testing for breast/ovarian cancer risk. Adjusting for survey year, high-risk women were more likely than average-risk women to have heard of genetic testing for cancer risk (RR, 1.3, 95% CI 1.2-1.4), to have discussed genetic testing with a health professional (RR 5.2, 95% CI 3.6-7.4), and to have undergone genetic testing for breast/ovarian cancer risk (RR 6.8, 95% CI 2.6-18.0).
conclusionsWe find low provision of guideline-recommended advice to women for whom testing may be appropriate and of significant clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.